Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Developments in newly diagnosed AML therapy in Europe: inspiring cooperation for tailored treatment

Bob Löwenberg • 24 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia

Bob Löwenberg, MD, PhD, of Erasmus University Medical Centre, Rotterdam, Netherlands, discusses developments in newly diagnosed acute myeloid leukemia (AML) therapy in Europe from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. Prof. Löwenberg explains how these new therapies may replace or add value to the standard 7+3 chemotherapy backbone, and highlights the need for multinational cooperation to recruit sufficient numbers of patients to trials.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Bob Löwenberg

Bob Löwenberg's perspective on CAR-T and immunotherapy for AML
1:28
Bob Löwenberg's perspective on CAR-T and immunotherapy for AML
Bob Löwenberg • 24 Feb 2019
Azacitidine maintance to improve DFS in elderly AML: HOVON-97 results
1:02
Azacitidine maintance to improve DFS in elderly AML: HOVON-97 results
Bob Löwenberg • 24 Feb 2019
How can we tackle treatment failure in ALL?
3:18
How can we tackle treatment failure in ALL?
Bob Löwenberg • 16 Apr 2018
The molecular heterogeneity of acute myeloid leukemia (AML) – new data and implications
4:57
The molecular heterogeneity of acute myeloid leukemia (AML) – new data and implications
Bob Löwenberg • 19 Feb 2017

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals